Grey Fox Wealth Advisors LLC Boosts Holdings in Eli Lilly and Company (NYSE:LLY)

Grey Fox Wealth Advisors LLC lifted its stake in Eli Lilly and Company (NYSE:LLY) by 4.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 997 shares of the company’s stock after purchasing an additional 44 shares during the quarter. Grey Fox Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $823,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently modified their holdings of the stock. WestEnd Advisors LLC raised its position in Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company’s stock worth $26,000 after buying an additional 21 shares during the last quarter. Citizens National Bank Trust Department raised its position in Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company’s stock worth $35,000 after buying an additional 27 shares during the last quarter. Financial Gravity Asset Management Inc. purchased a new position in Eli Lilly and Company in the 1st quarter worth about $40,000. Mascagni Wealth Management Inc. purchased a new position in Eli Lilly and Company in the 4th quarter worth about $43,000. Finally, O Brien Wealth Partners LLC raised its position in Eli Lilly and Company by 25.5% in the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company’s stock worth $49,000 after buying an additional 12 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Up 0.8%

Eli Lilly and Company stock opened at $799.51 on Tuesday. The firm has a 50 day moving average of $765.95 and a 200 day moving average of $800.18. The firm has a market capitalization of $757.72 billion, a price-to-earnings ratio of 65.05, a P/E/G ratio of 1.16 and a beta of 0.40. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a current ratio of 1.37, a quick ratio of 1.06 and a debt-to-equity ratio of 2.18.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). Eli Lilly and Company had a return on equity of 85.51% and a net margin of 22.67%. The firm had revenue of $12.73 billion during the quarter, compared to analysts’ expectations of $12.77 billion. During the same period in the prior year, the company posted $2.58 earnings per share. The company’s revenue was up 45.2% compared to the same quarter last year. As a group, research analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 10th. Shareholders of record on Friday, August 15th will be paid a $1.50 dividend. The ex-dividend date is Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.75%. Eli Lilly and Company’s payout ratio is 48.82%.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on LLY shares. UBS Group decreased their target price on Eli Lilly and Company from $1,100.00 to $1,050.00 and set a “buy” rating for the company in a research report on Friday, May 2nd. Morgan Stanley restated an “overweight” rating and set a $1,135.00 price target (up from $1,133.00) on shares of Eli Lilly and Company in a research note on Thursday. Wells Fargo & Company restated an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Guggenheim boosted their price target on Eli Lilly and Company from $936.00 to $942.00 and gave the company a “buy” rating in a research note on Friday. Finally, Hsbc Global Res downgraded Eli Lilly and Company from a “strong-buy” rating to a “moderate sell” rating in a research note on Monday, April 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,012.56.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.